RT Journal Article
SR Electronic
T1 Pretargeted Imaging and Therapy
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1553
OP 1559
DO 10.2967/jnumed.117.189944
VO 58
IS 10
A1 Altai, Mohamed
A1 Membreno, Rosemery
A1 Cook, Brendon
A1 Tolmachev, Vladimir
A1 Zeglis, Brian M.
YR 2017
UL http://jnm.snmjournals.org/content/58/10/1553.abstract
AB In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their pharmacokinetic limitations. The core premise of pretargeting lies in administering the targeting vector and radioisotope separately and having the 2 components combine within the body. In this manner, pretargeting strategies decrease the circulation time of the radioactivity, reduce the uptake of the radionuclide in healthy nontarget tissues, and facilitate the use of short-lived radionuclides that would otherwise be incompatible with antibody-based vectors. In this short review, we seek to provide a brief yet informative survey of the 4 preeminent mechanistic approaches to pretargeting, strategies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, and bioorthogonal click chemistry.